Pueraria Mirifica and Increased Vaginal Lactobacilli Levels

Time to effect

Median: 2.8 months · IQR 2.8 months–2.8 months · Range 2.8 months–2.8 months — Reported in 1 of 2 studies

Safety in these studies

c-reactive protein increasedIncreased riskdoubled
but serum C-reactive protein doubled
from: Efficacy and safety of Pueraria candollei var. mirifica (Airy Shaw & Suvat.) Niyomdham for
dizzinessNo significant difference
Adverse event rates (mastodynia, vaginal spotting, dizziness) were similar in all groups (PM, conjugated equine estrogen, and placebos)
from: Efficacy and safety of Pueraria candollei var. mirifica (Airy Shaw & Suvat.) Niyomdham for
mastodyniaNo significant difference
Adverse event rates (mastodynia, vaginal spotting, dizziness) were similar in all groups (PM, conjugated equine estrogen, and placebos)
from: Efficacy and safety of Pueraria candollei var. mirifica (Airy Shaw & Suvat.) Niyomdham for
vaginal spottingNo significant difference
Adverse event rates (mastodynia, vaginal spotting, dizziness) were similar in all groups (PM, conjugated equine estrogen, and placebos)
from: Efficacy and safety of Pueraria candollei var. mirifica (Airy Shaw & Suvat.) Niyomdham for

2 of 2 papers

Comparison of the effects of Pueraria mirifica gel and of placebo gel on the vaginal microenvironment of postmenopausal women with Genitourinary Syndrome of Menopause (GSM).